Ποια είναι η τιμή για Neumora Therapeutics, Inc. Common Stock (NMRA)

Η τιμή για Neumora Therapeutics, Inc. Common Stock (NMRA) είναι $1.38

Ποια είναι η κεφαλαιοποίηση αγοράς για Neumora Therapeutics, Inc. Common Stock (NMRA)

Η κεφαλαιοποίηση αγοράς για Neumora Therapeutics, Inc. Common Stock (NMRA) είναι $255.69M

Neumora Therapeutics, Inc. Common Stock (NMRA) Διαίρεση Μετοχών

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.